In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.
Video content above is prompted by the following question:
a. Given the data you’ve seen to date, how would you advise managed
a. With potential new treatment options on the horizon, how do you think payers should anticipate covering CSU in the next few years?
Pediatric Hidradenitis Suppurativa Linked to Gut Microbiome Dysregulation, Mental Health Connections
May 28th 2025Significant differences in gut microbiome composition were found among pediatric patients with hidradenitis suppurativa, suggesting further investigation surrounding gut microbiome dysregulation.
Read More
Future of Vitiligo Treatment: Emerging Therapies, Impact on Quality of Life
May 28th 2025Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted and effective treatments, though further research is needed to confirm their safety, efficacy, and optimal use.
Read More
Pediatric Hidradenitis Suppurativa Linked to Gut Microbiome Dysregulation, Mental Health Connections
May 28th 2025Significant differences in gut microbiome composition were found among pediatric patients with hidradenitis suppurativa, suggesting further investigation surrounding gut microbiome dysregulation.
Read More
Future of Vitiligo Treatment: Emerging Therapies, Impact on Quality of Life
May 28th 2025Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted and effective treatments, though further research is needed to confirm their safety, efficacy, and optimal use.
Read More
2 Commerce Drive
Cranbury, NJ 08512